MedCity News February 26, 2025
Eikon Therapeutics’ lead drug candidate is designed to activate toll-like receptors 7 and 8, sparking an immune response that fights cancer. Beyond this TLR7/8 agonist, the biotech is also developing PARP inhibitors that could have advantages over cancer drugs currently available from this class.
Eikon Therapeutics, a company headed by the former Merck executive who steered the cancer drug Keytruda to FDA approval, has raised $350.7 million to support a pipeline that includes a lead drug candidate now in a pivotal test that could support expanding melanoma treatment to a pair of new immunotherapy targets.
The lead Eikon drug, EIK1001, is a small molecule designed to hit toll-like receptors 7 and 8 (TLR7/8). Activating these receptors is intended to spark...
Today's Sponsors
Today's Sponsor